



UNIVERSITY OF LEEDS

This is a repository copy of *Knowledge of potential harms and benefits of tamoxifen among women considering breast cancer preventive therapy*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/155919/>

Version: Supplemental Material

Article:

Thorneloe, RJ, Hall, LH, Walter, FM et al. (3 more authors) (2020) Knowledge of potential harms and benefits of tamoxifen among women considering breast cancer preventive therapy. *Cancer Prevention Research*, 13 (4). pp. 411-422. ISSN 1940-6207

<https://doi.org/10.1158/1940-6207.CAPR-19-0424>

© 2020, American Association for Cancer Research. This is an author produced version of a paper published in *Cancer Prevention Research*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table S1. Univariable comparison of retention (n = 408)

Mean (\pm SD) for continuous variables; % (n) for categorical variables	Baseline only (n = 150)	Baseline and 3 months (n = 258)	P-value
Knowledge about harms and benefits			
Yes	12.6 (17)	17.3 (43)	0.242
No	87.4 (118)	82.7 (205)	
Satisfaction with healthcare professional			
Satisfaction score, mean \pm SD	19.30 \pm 3.68	19.30 \pm 3.83	0.987
Received a leaflet about tamoxifen			
Yes	68.0 (102)	72.9 (188)	0.310
No/unsure	32.0 (48)	27.1 (70)	
Felt informed about tamoxifen			
Yes	80.3 (118)	91.0 (233)	0.003
No	19.7 (29)	9.0 (23)	

P-value tests for significant differences between the 'baseline' and 'baseline and 3-month' cohorts using χ^2 tests and t-tests.

Table S2. Sensitivity analysis: Knowledge about benefits and ≥ 2 harms of tamoxifen by participant characteristics and univariable and multivariable logistic regression model (n =317)

Knowledge about benefits and ≥ 2 harms of tamoxifen (%; N)		Univariable		Multivariable	
		OR (95% CI)	P-value	OR (95% CI)	P-value
Age					
≤ 35 years	25.6 (10)	0.78 (0.34 – 1.79)	0.556	0.73 (0.23 – 2.26)	0.579
36 – 49 years	32.9 (80)	1.11 (0.67 – 1.83)	0.687	0.71 (0.37 – 1.36)	0.303
≥ 50 years	30.7 (31)	Ref		Ref	
Children					
Yes	33.1 (98)	1.38 (0.81 – 2.35)	0.240	1.61 (0.76 – 3.41)	0.219
No	26.4 (23)	Ref		Ref	
Ethnic group*					
White	31.2 (114)	-	-	-	-
Other	42.9 (6)	-	-	-	-
Education level					
Degree or above	43.3 (74)	2.67 (1.71 – 4.17)	≤ 0.001	2.95 (1.68 – 5.18)	≤ 0.001
Below degree level	22.2 (46)	Ref		Ref	
Health status					
Poor*	33.3 (5)	-	-	-	-
Fair	16.2 (12)	0.39 (0.17 – 0.88)	0.023	0.47 (0.18 – 1.18)	0.108
Good	36.2 (83)	1.14 (0.62 – 2.07)	0.675	1.14 (0.57 – 2.29)	0.713
Excellent	33.3 (20)	Ref		Ref	
Risk level					
Moderate	35.5 (81)	1.57 (1.00 – 2.47)	0.052	1.79 (1.03 – 3.14)	0.041
High	26.0 (39)	Ref		Ref	
Unclear*	20.0 (1)	-	-	-	-
SES					
Low (most deprived)	28.6 (32)	0.77 (0.45 – 1.33)	0.354	1.06 (0.55 – 2.04)	0.860
Middle	31.5 (40)	0.89 (0.53 – 1.49)	0.657	0.900 (0.48 – 1.70)	0.742
High (least deprived)	34.1 (47)	Ref		Ref	

Employment					
Full-time	31.0 (102)	Ref		Ref	
All other employments	35.2 (19)	1.21 (0.66 – 2.21)	0.540	1.88 (0.91 – 3.90)	0.089
Marital status					
Married or cohabiting	32.3 (91)	1.06 (0.65 – 1.75)	0.807	1.15 (0.59 – 2.26)	0.686
Unmarried	30.9 (30)	Ref		Ref	
Numeracy					
Good numeracy	34.0 (104)	1.99 (1.05 – 3.74)	0.034	2.43 (1.09 – 5.40)	0.030
Poor numeracy	20.6 (14)	Ref		Ref	
Received a leaflet about tamoxifen					
Yes	34.7 (95)	1.69 (1.02 – 2.81)	0.041	1.14 (0.61 – 2.12)	0.684
No/unsure	23.9 (26)	Ref		Ref	
Satisfaction with healthcare professional					
Satisfaction score, mean \pm SD	19.44 (3.44)	1.02 (0.96 – 1.08)	0.629	0.99 (0.93 – 1.07)	0.836
Felt informed about tamoxifen					
Yes	34.5 (115)	3.69 (1.52 – 8.95)	0.004	3.73 (1.18 – 11.79)	0.025
No	12.5 (6)	Ref		Ref	

*category not included in univariable and multivariable analyses due to insufficient cases.

*= This variable included the potential benefit of tamoxifen (a reduction in breast cancer risk) and at least two of the three potential harms of tamoxifen (increased risk of menopausal symptoms, blood clotting and endometrial cancer). In total, 31.6% (121) of women identified the benefit and ≥ 2 harms of tamoxifen.

Table S3. Knowledge about the potential harms and benefits of tamoxifen by participant characteristics and univariable and multivariable logistic regression model, with missing data reported as poor knowledge (n=332)

Good knowledge ⁺ (%; N)		Univariable		Multivariable	
		OR (95% CI)	P-value	OR (95% CI)	P-value
Age					
≤ 35 years	9.8 (4)	0.66 (0.21 – 2.13)	0.490	0.50 (0.11 – 2.43)	0.393
36 – 49 years	15.8 (41)	1.18 (0.62 – 2.24)	0.611	0.69 (0.30 – 1.59)	0.387
≥ 50 years	13.9 (15)	Ref		Ref	
Children					
Yes	15.3 (48)	1.23 (0.63 – 2.43)	0.545	1.47 (0.57 – 3.76)	0.425
No	12.8 (12)	Ref		Ref	
Ethnic group*					
White	14.3 (55)	-	-	-	-
Other	22.2 (4)	-	-	-	-
Education level					
Degree or above	21.6 (38)	2.50 (1.42 – 4.42)	0.002	2.47 (1.23 – 4.97)	0.011
Below degree level	9.9 (22)	Ref		Ref	
Health status					
Poor*	18.8 (3)	-	-	-	-
Fair	6.4 (5)	0.38 (0.12 – 1.19)	0.096	0.40 (0.11 – 1.46)	0.166
Good	17.5 (42)	1.19 (0.56 – 2.52)	0.653	1.16 (0.50 – 2.68)	0.737
Excellent	15.2 (10)	Ref		Ref	
Risk level					
Moderate	17.7 (43)	1.80 (0.98 – 3.28)	0.056	1.94 (0.94 – 4.00)	0.075
High	10.7 (17)	Ref		Ref	
Unclear*	0.0 (0)	-	-	-	-
SES					
Low (most deprived)	13.3 (16)	0.84 (0.42 – 1.68)	0.630	1.01 (0.44 – 2.29)	0.986
Middle	14.5 (19)	0.95 (0.49 – 1.83)	0.872	0.93 (0.42 – 2.06)	0.862
High (least deprived)	15.3 (23)	Ref		Ref	

Employment					
Full-time	15.2 (53)	Ref		Ref	
All other employments	11.7 (7)	0.72 (0.31 – 1.67)	0.444	1.13 (0.44 – 2.91)	0.799
Marital status					
Married or cohabiting	15.4 (46)	1.14 (0.59 – 2.17)	0.701	1.00 (0.44 – 2.29)	0.998
Unmarried	13.6 (14)	Ref		Ref	
Numeracy					
Good numeracy	18.0 (58)	7.70 (1.83 – 32.30)	0.005	6.14 (1.39 – 27.09)	0.017
Poor numeracy	2.8 (2)	Ref		Ref	
Received a leaflet about tamoxifen					
Yes	16.9 (49)	1.98 (0.99 – 3.95)	0.054	1.52 (0.65 – 3.55)	0.334
No/unsure	9.3 (11)	Ref		Ref	
Satisfaction with healthcare professional					
Satisfaction score, mean \pm SD	19.34 \pm 3.55	1.00 (0.93 – 1.08)	0.936	0.97 (0.89 – 1.06)	0.554
Felt informed about tamoxifen					
Yes	16.5 (58)	4.95 (1.17 – 20.91)	0.030	5.49 (0.69 – 43.73)	0.108
No	3.8 (2)	Ref		Ref	

*category not included in univariable and multivariable analyses due to insufficient cases.

*= This variable included the potential benefit of tamoxifen (a reduction in breast cancer risk) and three potential harms of tamoxifen (increased risk of menopausal symptoms, blood clotting and endometrial cancer).

Table S4. Still deciding about tamoxifen on the subjective decision quality scale, by participant characteristics and univariable and multivariable logistic regression model (n=216)

Still deciding (%; N)		Univariable		Multivariable	
		OR (95% CI)	P-value	OR (95% CI)	P-value
Age					
≤ 35 years	37.0 (10)	0.55 (0.22 – 1.40)	0.208	0.57 (0.17 – 1.91)	0.361
36 – 49 years	41.1 (69)	0.65 (0.36 – 1.17)	0.154	0.70 (0.34 – 1.44)	0.334
≥ 50 years	51.6 (32)	Ref		Ref	
Children					
Yes	43.8 (89)	1.14 (0.62 – 2.09)	0.683	0.94 (0.41 – 2.15)	0.878
No	40.7 (22)	Ref		Ref	
Ethnic group					
White	43.1 (106)	1.51 (0.37 – 6.19)	0.564	1.02 (0.21 – 5.05)	0.983
Other	33.3 (3)	Ref		Ref	
Education level					
Degree or above	35.9 (42)	0.59 (0.35 – 0.97)	0.037	0.72 (0.38 – 1.39)	0.329
Below degree level	48.9 (68)	Ref		Ref	
Health status					
Poor	45.5 (5)	1.62 (0.43 – 6.11)	0.481	2.92 (0.58 – 14.60)	0.193
Fair	44.7 (21)	1.57 (0.68 – 3.60)	0.292	1.56 (0.59 – 4.14)	0.373
Good	45.3 (68)	1.61 (0.81 – 3.18)	0.174	1.31 (0.58 – 2.96)	0.512
Excellent	34.0 (16)	Ref		Ref	
Risk level					
Moderate	37.6 (59)	0.58 (0.35 – 0.96)	0.035	0.70 (0.38 – 1.29)	0.251
High	51.0 (50)	Ref		Ref	
Unclear*	2 (100)	-	-	-	-
SES					
Low (most deprived)	45.9 (28)	1.08 (0.58 – 2.04)	0.804	0.69 (0.31 – 1.52)	0.360
Middle	40.0 (34)	0.85 (0.48 – 1.52)	0.584	0.55 (0.27 – 1.13)	0.105
High (least deprived)	43.9 (47)	Ref		Ref	

Employment					
Full-time	43.2 (95)	Ref		Ref	
All other employments	43.2 (16)	1.00 (0.50 – 2.03)	0.994	1.07 (0.47 – 2.48)	0.868
Marital status					
Married or cohabiting	41.6 (82)	0.74 (0.41 – 1.32)	0.307	0.96 (0.44 – 2.06)	0.909
Unmarried	49.2 (29)	Ref		Ref	
Numeracy					
Good numeracy	42.3 (88)	0.84 (0.44 – 1.63)	0.613	1.03 (0.46 – 2.33)	0.940
Poor numeracy	46.5 (20)	Ref		Ref	
Received a leaflet about tamoxifen					
Yes	44.4 (83)	1.20 (0.69 – 2.09)	0.528	1.22 (0.61 – 2.45)	0.573
No/unsure	40.0 (28)	Ref		Ref	
Satisfaction with healthcare professional					
Satisfaction score, mean \pm SD	18.28 \pm 3.57	0.88 (0.82 – 0.95)	0.001	0.88 (0.81 – 0.96)	0.003
Felt informed about tamoxifen					
Yes	40.8 (95)	0.37 (0.15 – 0.90)	0.029	0.64 (0.21 – 1.90)	0.419
No	65.2 (15)	Ref		Ref	
Knowledge about harms and benefits					
Yes	38.6 (17)	0.81 (0.41 – 1.57)	0.522	1.04 (0.47 – 2.33)	0.919
No	43.9 (90)	Ref		Ref	

*category not included in univariable and multivariable analyses due to insufficient cases.